Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2A6 | P11509 | 4/20 | 0.54 |
| ▸ | ASIC3 | Q9UHC3 | 1/20 | 0.54 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.54 |
| ▸ | AGXT | P21549 | 1/20 | 0.50 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.46 |
| ▸ | CA2 | P00918 | 1/20 | 0.40 |
| ▸ | MMP1 | P03956 | 1/20 | 0.40 |
| ▸ | FCER2 | P06734 | 1/20 | 0.40 |
| ▸ | ADRA1D | P25100 | 2/20 | 0.39 |
| ▸ | ALOX5 | P09917 | 4/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.38 |
| ▸ | PTGES | O14684 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | LTA4H | P09960 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.38 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.38 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.38 |
| ▸ | LOX | P28300 | 1/20 | 0.38 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2264402 | 1.00 | CYP2A6 (0.54) | CYP2A6ASIC3LOXL2AGXTADRB2 | |
| SCHEMBL2267370 | 1.00 | CYP2A6 (0.54) | CYP2A6ASIC3LOXL2AGXTADRB2 | |
| SCHEMBL30905568 | 0.78 | CYP2A6 (0.59) | CYP2A6ASIC3LOXL2AGXTADRB2 | |
| SCHEMBL20912808 | 0.78 | CYP2A6 (0.59) | CYP2A6ASIC3LOXL2AGXTADRB2 | |
| SCHEMBL3459782 | 0.78 | CYP2A6 (0.59) | CYP2A6ASIC3LOXL2AGXTADRB2 | |
| SCHEMBL19760753 | 0.78 | CYP2A6 (0.59) | CYP2A6ASIC3LOXL2AGXTADRB2 | |
| SCHEMBL6637521 | 0.78 | CYP2A6 (0.59) | CYP2A6ASIC3LOXL2AGXTADRB2 | |
| SCHEMBL2639276 | 0.77 | CYP2A6 (0.54) | CYP2A6ASIC3LOXL2AGXTADRB2 | |
| SCHEMBL2638016 | 0.77 | CYP2A6 (0.54) | CYP2A6ASIC3LOXL2AGXTADRB2 | |
| SCHEMBL4626056 | 0.76 | CYP2A6 (0.53) | CYP2A6ASIC3LOXL2AGXTADRB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 47 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110195898-A1 | TREATMENT OF ALZHEIMER'S DISEASE AND MILD COGNITIVE IMPAIRMENT USING GNRH-I ANALOGS AND ONE OR MORE OF ACETYLCHOLINESTERASE INHIBITORS AND NMDA RECEPTOR ANTAGONISTS | VOYAGER PHARMACEUTICAL CORPORATION (US) | 2011-08-11 | — | — | US | claimed |
| US-20080171736-A1 | Treatment of Alzheimer's Disease and Mild Cognitive impairment using GnRH-I analogs and one or more of acetylcholinesterase inhibitors and NMDA receptor antagonists | VOYAGER PHARMACEUTICAL CORPORATION | 2008-07-17 | — | — | US | claimed |
| EP-0683792-B1 | LHRH ANTAGONISTS HAVING MODIFIED AMINOACYL RESIDUES AT POSTIONS 5 AND 6 | ABBOTT LAB (US) | 2001-09-26 | — | — | EP | claimed |
| EP-0673254-A4 | 6-POSITION MODIFIED DECAPEPTIDE LHRH ANTAGONISTS. | ABBOTT LAB (US) | 1998-11-18 | — | — | EP | claimed |
| EP-0683792-A4 | LHRH ANTAGONISTS HAVING MODIFIED AMINOACYL RESIDUES AT POSTIONS 5 AND 6. | ABBOTT LAB (US) | 1998-11-18 | — | — | EP | claimed |
| US-5698522-A | INHIBIT RELEASE OF LUTEINIZING HORMONE RELEASING HORMONE | ABBOTT LABORATORIES (US) | 1997-12-16 | — | — | US | claimed |
| JP-H09501913-A | — | — | 1997-02-25 | — | — | JP | claimed |
| EP-0738154-A1 | N-TERMINUS MODIFIED ANALOGS OF LHRH | Abbott Laboratories (US) | 1996-10-23 | — | — | EP | claimed |
| JP-H08505611-A | — | — | 1996-06-18 | — | — | JP | claimed |
| JP-H08504209-A | — | — | 1996-05-07 | — | — | JP | claimed |
| WO-1995004540-A1 | N-TERMINUS MODIFIED ANALOGS OF LHRH | ABBOTT LABORATORIES (US) | 1995-02-16 | — | — | WO | claimed |
| WO-1995004541-A1 | N-TERMINUS MODIFIED ANALOGS OF LHRH | ABBOTT LABORATORIES (US) | 1995-02-16 | — | — | WO | claimed |
| WO-1994014841-A1 | LHRH ANTAGONISTS HAVING MODIFIED AMINOACYL RESIDUES AT POSTIONS 5 AND 6 | ABBOTT LABORATORIES (US) | 1994-07-07 | — | — | WO | claimed |
| WO-1994013313-A1 | 6-POSITION MODIFIED DECAPEPTIDE LHRH ANTAGONISTS | ABBOTT LABORATORIES (US) | 1994-06-23 | — | — | WO | claimed |
| US-5110904-A | Luteinizing hormone releasing hormone; suppression of sex hormones | ABBOTT LABORATORIES (US) | 1992-05-05 | — | — | US | claimed |
| EP-0417454-A2 | Reduced size LHRH analogs | ABBOTT LABORATORIES (US) | 1991-03-20 | — | — | EP | claimed |
| EP-0413209-A1 | LHRH analogs | TAP Pharmaceuticals Inc. (US) | 1991-02-20 | — | — | EP | claimed |
| EP-0145032-B1 | LH- RH ANTAGONISTS | AKZO N.V. (NL) | 1987-11-04 | — | — | EP | claimed |
| US-4628044-A | LHRH antagonists | AKZO N.V. (NL) | 1986-12-09 | — | — | US | claimed |
| EP-0145032-A1 | LH- RH Antagonists | AKZO N.V. (NL) | 1985-06-19 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110195898-A1 | TREATMENT OF ALZHEIMER'S DISEASE AND MILD COGNITIVE IMPAIRMENT USING GNRH-I ANALOGS AND ONE OR MORE OF ACETYLCHOLINESTERASE INHIBITORS AND NMDA RECEPTOR ANTAGONISTS | GNRHR, GRIN1, GRIN3A | CYP2A6 3402/4885ASIC3 4355/4885LOXL2 4664/4885 |
| US-20080171736-A1 | Treatment of Alzheimer's Disease and Mild Cognitive impairment using GnRH-I analogs and one or more of acetylcholinesterase inhibitors and NMDA receptor antagonists | GNRHR, GRIN1, GRIN3A | CYP2A6 3402/4885ASIC3 4355/4885LOXL2 4664/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.